menu toggle

Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies

By AmerisourceBergen

Cell and gene therapies hold the promise to revolutionize healthcare by introducing groundbreaking advancements for patients with diseases that were previously thought incurable. Given the unique characteristics and curative potential of these therapies, it is crucial that US healthcare decision-makers apply evidence-based methods when assessing the value of these treatments to promote meaningful patient access to needed medications while maintaining health system sustainability.

Recognizing the distinctive attributes of cell and gene therapies, the Institute for Clinical and Economic Review (ICER) released methods adaptations to its value assessment framework for assessing high-impact single and short-term therapies (SST). Cencora examined the underlying methodology of ICER’s SST framework and identified important considerations related to ICER’s application of these methods in its assessments. 

Download our issue brief that highlights the importance of:
  • Applying fit-for-purpose, evidence-based value assessment methods when evaluating the value of cell and gene therapies
  • Identifying opportunities to address methodological limitations associated with ICER’s SST framework

Connect with our team

From market-shaping and disease awareness efforts to conducting full POA meeting and training engagements, our unique collaboration between science, design, and client services generates innovative work that resonates with formulary decision makers.